SIGA Technologies Soars as EU is in Talks to Buy Monkeypox Therapeutics and Vaccines
SIGA Technologies skyrocketed 42% today among news that the EU is in talks to buy monkeypox therapeutics and vaccines.
This is good news for SIGA as the Company’s TPOXX formulation has recently been approved in Europe for indications including smallpox and monkeypox.
There are now over 100 cases of monkeypox worldwide, spreading to multiple continents and SIGA technologies may be well positioned to tackle the outbreak.
SIGA technologies is housed in the PRISM Vaccines & Cell Therapy index, which shot up 6.6% for the day.